Products

AZD-9291 mesylate, also known as osimertinib mesylate, is a targeted therapy drug used in the treatment of non-small cell lung cancer (NSCLC). It belongs to a class of drugs called tyrosine kinase inhibitors (TKIs) and is specifically used for NSCLC cases that have a specific mutation known as epidermal growth factor receptor (EGFR) T790M.EGFR mutations are commonly found in NSCLC patients, and they play a crucial role in the development and progression of the disease. However, conventional EGFR inhibitors may become ineffective over time due to the emergence of the T790M mutation. AZD-9291 mesylate is designed to selectively target this specific mutation, making it a highly effective treatment option for patients who have developed resistance to other EGFR inhibitors.The drug works by irreversibly binding to the mutant EGFR receptor and inhibiting its activity. This prevents further tumor growth and leads to cancer cell death. This unique mechanism of action makes AZD-9291 mesylate highly effective in treating NSCLC patients with the T790M mutation.AZD-9291 mesylate is administered orally in the form of tablets. The recommended dosage may vary depending on the patient's individual characteristics and treatment response. It is generally taken once daily with or without food. It is important to follow the prescribed dosing schedule and consult with a healthcare professional before making any adjustments.As with any medication, there are potential side effects associated with AZD-9291 mesylate. Common side effects may include diarrhea, rash, fatigue, nausea, and decreased appetite. Serious side effects such as interstitial lung disease and QT prolongation have also been reported, although they are relatively rare.Regular monitoring of blood tests and cardiac function may be necessary during treatment to ensure the drug's safety and efficacy. It is essential to communicate any concerning symptoms or adverse effects to a healthcare professional promptly.In summary, AZD-9291 mesylate is a targeted therapy drug used for the treatment of NSCLC with the T790M mutation. Its unique mechanism of action makes it effective in overcoming resistance to other EGFR inhibitors. While it can be associated with potential side effects, regular monitoring and communication with a healthcare professional can help manage these and ensure the drug's effectiveness in improving patient outcomes.